Dorixina

There is no image.

Clonixin

Method of action: Analgesic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dorixina

Property	Description
Active Ingredient	Clonixin lysine
Form	Oral tablets, solution for injection
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose	Pain relief (analgesia) and inflammation management
Origin	Synthetic (Anthranilic acid derivative)

What Type of Medicine is Dorixina (Clonixin Lysine)?

Dorixina is the trade name for the active substance Clonixin lysine, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medicine is a synthetic compound belonging to the Anthranilic acid derivative chemical class, a specific subgroup of NSAIDs, and is structured as a single-entity product. Its identity as an NSAID establishes its fundamental pharmacological role, differentiating it from other major classes of pain relievers, such as pure opioids or centrally-acting analgesics, by targeting inflammation.

Defining the Pharmacological Class and Available Forms

Clonixin lysine is fundamentally defined by its NSAID pharmacological class, granting it inherent analgesic and anti-inflammatory capabilities. The substance is recognized for providing relief through prostaglandin synthesis inhibition. This means the medicine works by reducing the body’s production of chemicals that cause pain and swelling. The medicine is manufactured in various dosage forms to accommodate different therapeutic requirements. Notably, Dorixina is recognized for its forms that allow for diverse administration, including standard oral tablets and specialized dosage units such as enteric-coated tablets, as well as an aqueous solution for injection (ampoules). This availability allows for both oral and parenteral routes of administration, offering necessary flexibility in its therapeutic application.

What is the General Therapeutic Purpose of Clonixin Lysine?

The general therapeutic purpose of Clonixin lysine is to provide effective symptomatic treatment by targeting both the sensation of pain and the biological process of inflammation simultaneously. The drug works peripherally, meaning its action is primarily located at the site of the issue, reducing the production of localized chemical mediators that cause discomfort and swelling. This combined action ensures comprehensive relief, establishing its core value in the management of conditions characterized by both pain and associated tissue inflammation, such as temporary musculoskeletal discomfort. This application is based on its role in general pain and inflammation management.

What side effects are possible with Dorixina?

Possible side effects and safety information for Dorixina (Clonixin Lysine)

Clonixin lysine, as an Nonsteroidal Anti-inflammatory Drug (NSAID), has an official safety profile structured by frequency and the body system affected, consistent with regulatory standards. Adverse reactions are formally classified into categories such as Common, Uncommon, and Rare in official prescribing information.

System-Organ Classes and Documented Adverse Reactions

Adverse effects are grouped by System-Organ Classes (SOC), primarily affecting the Gastrointestinal and Nervous Systems. Common reactions documented in regulatory sources typically include gastrointestinal symptoms such as dyspepsia, nausea, and abdominal pain, alongside headache and dizziness.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights the potential for serious adverse reactions, a class effect of NSAIDs. These include the risk of gastrointestinal bleeding, ulceration, and perforation, and the potential for cardiovascular thrombotic events (e.g., stroke, myocardial infarction). The risk of serious gastrointestinal events is officially noted to be associated with the duration of use and higher doses.

Specific regulatory constraints define when the medicine should not be used. It is contraindicated in patients with conditions such as active peptic ulcer, severe hepatic failure, severe renal failure, or severe heart failure.

Population-Specific Notes

The official safety information notes that older adults have an increased risk of serious gastrointestinal and renal adverse events. These explicit safety boundaries and risk classifications establish the regulatory framework for using the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented approach to overdose for Dorixina (Clonixin lysine), strictly based on the information specified in government regulatory prescribing documents.

Overdose Scope: Officially Documented Response

In the event of massive ingestion or suspected overdose, regulatory authorities mandate that patients seek immediate medical attention at the nearest hospital or approved assistance center. This urgent action is required regardless of the initial clinical presentation.

Overdose Factor	Official Regulatory Statement
Specific Antidote	No specific antidote is known for Clonixin lysine.
Immediate Procedure	Gastric lavage and administration of activated charcoal are described as immediate procedural steps for oral intoxication.
Required Monitoring	Observation and control of vital functions are mandated procedures. Monitoring should also include assessment of renal and gastroduodenal functions due to the nature of the active substance.
Clinical Presentation	Specific symptoms are not fixed or enumerated in a comprehensive list; treatment must be symptomatic and supportive, administered strictly according to the clinical picture observed in the patient.

The official overdose profile centers on the urgency of risk mitigation due to the lack of an antidote, necessitating immediate supportive care. The regulatory requirement to control vital functions underscores the potential for systemic compromise following massive ingestion.

Therapeutic Uses of Dorixina

What Dorixina Treats: Main Uses and Benefits

Symptomatic Management of Pain and Localized Inflammation

Dorixina (Clonixin lysine) is relevant for symptomatic support across pain syndromes characterized by discomfort and inflammation. The compound is commonly applied in situations where symptoms related to physical discomfort are driven by inflammatory or irritative states, such as soft tissue disorders and managing pain related to chronic arthritic conditions. This therapeutic domain contributes to easing day-to-day comfort during periods of heightened symptoms by easing the overall symptom burden of pain and swelling.

Relief for Acute Visceral Discomfort and Colic

It is also considered relevant in contexts involving heightened systemic burden and symptoms that create noticeable physiological strain from intense, often spasmodic pain. The medication may assist with managing conditions like renal colic and pronounced discomfort from primary dysmenorrhea (menstrual pain), which contributes to helping patients cope more steadily with difficult episodes.

Support for Severe Headaches and Post-Procedure Pain

Applied across domains where additional symptomatic support is needed, Dorixina is relevant for easing discomfort following minor surgical procedures or trauma. It is also used for managing acute, severe forms of headache, including migraine attacks. This may help patients cope more steadily with symptom fluctuations when discomfort interferes with daily functioning.

Quick Fact: Supportive Focus on Acute Symptom Management

The medication is relevant for managing symptoms associated with acute or episodic changes, such as sharp colic or severe episodic headaches.

Eligibility and Restrictions for Use

Dorixina (Clonixin lysine) eligibility is determined by specific regulatory criteria, establishing who can and cannot use this Nonsteroidal Anti-inflammatory Drug (NSAID). Use is generally permitted for the adult population, provided no formal contraindications or specific restrictions apply. The following population groups have formal eligibility restrictions:

Eligibility Status	Affected Population or Condition
Contraindicated (Must not use)	Pediatric population (Children); Patients with known hypersensitivity to the drug or its excipients.
Use with Caution (Restricted/Monitored)	Patients with renal impairment or hepatic impairment; Individuals with pre-existing cardiovascular conditions, including severe hypertension or coronary disease.
Not Recommended (Data insufficient)	Women who are breastfeeding (an alternate drug is preferred due to lack of safety data); Pregnancy (caution required, consistent with NSAID class restrictions).

The official regulatory profile strictly limits use based on age and pre-existing health status. Use is absolutely prohibited for children and those with documented hypersensitivity. For older adults and patients with impaired kidney or liver function, use is conditional and requires close medical oversight, defining the eligible population as adults free of specific health contraindications.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Dorixina (clonixin/clonixin lysine) is a non-steroidal anti-inflammatory drug (NSAID) whose pharmacological actions can be affected by, or affect, other medications. Always consult a healthcare provider to review your complete medication list, including over-the-counter drugs, supplements, and herbal remedies, before starting this treatment.

Key Drug Interactions to Monitor:

Drug Class	Potential Interaction	Resulting Risk
Other NSAIDs/Aspirin	Additive effects on prostaglandin synthesis	Increased risk of gastrointestinal (GI) bleeding and kidney impairment.
Anticoagulants (e.g., Warfarin)	Increased inhibition of platelet function	Higher risk of bleeding and hemorrhage. Dosage monitoring is necessary.
Antihypertensive Drugs (e.g., ACE inhibitors, ARBs, Diuretics)	Reduction of blood pressure-lowering effects	Reduced efficacy of the blood pressure medication, potentially leading to uncontrolled hypertension.
SSRIs/SNRIs (Certain Antidepressants)	Additive risk of blood thinning	Increased risk of bleeding, particularly GI bleeding.
Methotrexate	Reduced renal excretion of methotrexate	Increased methotrexate toxicity, requiring close monitoring of drug levels.

Simultaneous use of Dorixina with multiple NSAIDs should be avoided. Additionally, the use of alcohol may increase the risk of gastrointestinal adverse effects associated with NSAIDs and should be limited during treatment.

Mechanism of Action

How Dorixina Works: Mechanism of Action

Dorixina (Clonixin lysine) operates primarily by functioning as an inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This molecular action blocks the conversion of Arachidonic Acid into Prostaglandins, lipid mediators that regulate inflammatory signaling and sensitize peripheral nerve endings. This interference in the Arachidonic Acid Cascade results in a physiological decrease in peripheral nociceptor excitability and a limitation of localized fluid accumulation.

The mechanism also includes inhibitory activity against 5-Lipoxygenase (5-LOX) and modulation of Inducible Nitric Oxide Synthase (iNOS). By affecting these parallel pathways, the mechanism influences multiple components of the overall inflammatory cascade, dictating how vascular permeability and tissue response are regulated. The systemic consequence of reduced Prostaglandins is the desensitization of peripheral nociceptors, ensuring the mechanism is activated directly at the site of peripheral signal generation. The drug is constrained from causing significant, sustained inhibition of platelet aggregation typically associated with a full COX-1 blockade.

Dosage and Administration Information

Dorixina, which contains the active ingredient Clonixin lysine, is administered via two official routes: orally, typically using tablets, or intravenously (IV) as a solution for injection. The labeled dosing and administration rules are specific to the route and clinical context.

Official Administration and Dosing

Instruction	Official Details
Administration Route	Oral (tablet) or Intravenous (IV) injection.
Standard Adult Dose	Oral: One to two tablets per dose, with common strengths being 125 mg, 250 mg, or 300 mg. IV: A single dose of 200 mg is typically advised.
Dosing Frequency	Oral administration is generally scheduled with an interval of every 8 hours, meaning up to three times daily.
Duration	Use is typically limited to short-term treatment courses, such as for a period of seven to ten days, or for acute episodes.

Procedural and Population Constraints

The intravenous form is intended for use in an acute setting, such as for managing pain following certain procedures, and must be administered within a supervised healthcare environment. Consistent with general nonsteroidal anti-inflammatory drug (NSAID) principles, the procedural rule is to use the lowest effective daily dose for the shortest required duration. The product’s safety and efficacy have not been established in the pediatric population, and its use is therefore not recommended for children. No high-level instruction exists in official documentation that dictates taking the oral form strictly with or without food.

Recent Clinical Evidence

Dorixina: Recent Clinical Evidence

Evidence for use in Acute Pain Management

Clonixin lysine was evaluated in trials exploring short-term symptom changes, often related to acute physical discomfort following minor procedures. Studies explored outcomes related to physical discomfort and the time until individuals reported a change in their symptoms. Research also explored scenarios involving conditions characterized by fluctuating or episodic manifestations, such as mild to moderate lower back pain. Data show patterns related to symptom measurements over defined time intervals, but these trials often monitored the compound as part of a fixed-dose combination, which contributes to uncertainty when trying to isolate the specific evidence for Clonixin lysine alone. Follow-up durations were limited, focusing on immediate results.

Evidence for use in Acute Migraine Attacks

Research explored scenarios involving conditions associated with acute or disruptive episodes, specifically migraine attacks. Studies explored outcomes related to physical discomfort and the time until perceived relief, using double-blind, placebo-controlled designs. Findings indicate patterns related to the initial pain intensity. Research describes changes measured during the study period for participants experiencing moderate attacks. However, some studies reported no meaningful difference between the oral form and placebo in the setting of severe headache intensity. The intravenous form was studied for severe migraine. Long-term effects are not fully established.

Evidence in Special Populations and Research Gaps

Clonixin lysine was studied for outcomes related to physical discomfort in older adults in the context of osteoarthritis pain. However, results apply only to the populations studied—elderly individuals with knee osteoarthritis. Data for other groups, such as younger patients, remain insufficient.

For the pediatric population, specialized studies monitored the compound's absorption and processing in the body (pharmacokinetic outcomes) in a small number of children. For pregnancy and breastfeeding, comprehensive data on the compound's use during these periods remains insufficient. Evidence quality varies across the research landscape, and certainty remains low in areas requiring long-term follow-up.

Key Studies & References

Clonixin - Drugs and Lactation Database (LactMed®)

Frequently Asked Questions (FAQ)

Common questions about Dorixina (FAQ)

Q: Can Dorixina be used for menstrual cramps?

A: Yes, official product information indicates that the active ingredient, clonixin lysine, is indicated for the relief of pain associated with various conditions, including menstrual cramps, which is medically referred to as dysmenorrhea.

Q: Is Dorixina effective for dental pain or toothaches?

A: According to regulatory indications, Dorixina is indicated for managing different types of pain. This includes pain associated with dental conditions or toothaches (odontalgia).

Q: Is it normal to feel dizzy or drowsy after taking Dorixina?

A: The official safety profile for the active ingredient is associated with central nervous system (CNS) side effects such as dizziness. It is important to note that related effects like drowsiness (somnolence) are associated with medications that affect the CNS.

Q: Are there any long-term side effects associated with regular Dorixina use?

A: Official information generally limits the use of this medicine to short-term treatment courses, such as for acute pain episodes. Regulatory warnings note that the risk of serious side effects, particularly gastrointestinal events like bleeding, is reported to increase with longer duration of use or at higher doses.

Q: Can Dorixina affect your kidney function?

A: As with other non-steroidal anti-inflammatory drugs (NSAIDs), Dorixina may be associated with risks to kidney function. For this reason, the medicine is contraindicated in patients with severe renal (kidney) failure, and individuals with existing kidney issues may require medical monitoring.

Q: Does Dorixina have any warnings for people with heart conditions?

A: Yes, regulatory documents for NSAIDs like Dorixina include warnings about the potential for serious cardiovascular thrombotic events, such as heart attack or stroke. This risk is typically associated with longer use and higher doses.

Q: Can I take Dorixina while I am breastfeeding?

A: Official regulatory data on the use of clonixin lysine during breastfeeding is insufficient. Therefore, an alternate drug is generally preferred for nursing women, particularly those with a newborn or preterm infant.

Q: Is Dorixina suitable for people with a history of ulcers?

A: Dorixina is strictly contraindicated (must not be used) in patients who have an active peptic ulcer. A history of ulcers is a factor that necessitates medical evaluation before the medicine can be considered, as all NSAIDs carry a risk of serious gastrointestinal events.

Q: What are the signs of taking too much Dorixina?

A: If excessive amounts of the drug are taken, symptoms may occur related to the central nervous system, such as changes in consciousness or balance, and the gastrointestinal system, such as nausea, vomiting, or stomach pain. The possibility of serious toxicity exists with high doses.

Q: Does Dorixina make you feel tired during the day?

A: The medicine's active substance is associated with central nervous system effects, and its safety profile may include side effects like dizziness. Therefore, it is important to be aware of the possibility of feeling tired or drowsy (somnolence) when using medications that affect the nervous system.

Q: Why is Dorixina sometimes used for post-surgery pain?

A: According to official therapeutic indications, Dorixina is indicated for the relief of pain associated with various conditions, including discomfort following surgery or trauma.

Q: Is it safe to drive after taking a dose of Dorixina?

A: The active ingredient has the potential to cause side effects such as dizziness and drowsiness. Due to this potential, product labeling recommends caution and advises against driving or operating heavy machinery until an individual is aware of how the medicine affects them.

Q: What is the research evidence supporting the use of Dorixina for muscle pain?

A: The active substance clonixin lysine is officially indicated for the relief of various painful conditions. This includes indications specifically for muscular pain.

Q: How soon after stopping Dorixina does the drug fully leave the body?

A: The drug's elimination is described in pharmacokinetic studies. After intravenous administration, the time it takes for half the drug to be eliminated (the half-life) is approximately 30 to 50 minutes.

Q: Can Dorixina be used for chronic pain management?

A: The official product information typically recommends the product for short-term use or acute pain episodes, such as for a course of seven to ten days. Using the medication over a prolonged period for chronic pain is associated with an increased risk of serious side effects.

Q: Does Dorixina help with nerve pain?

A: Studies indicate that clonixin lysine has demonstrated efficacy in managing various pain syndromes. This includes pain associated with nerve compression.

Q: What is the maximum daily limit for Dorixina intake?

A: The oral dose is typically administered up to three times per day. Typical single doses in regulatory documents do not exceed 300 mg.

How should Dorixina be stored and disposed of?

How to Store and Dispose of Dorixina?

Storage and disposal requirements for Dorixina (Clonixin lysine) are based on general pharmaceutical mandates and official handling requirements for the active ingredient.

Storage Conditions

Requirement	Description
Child Safety	Must be stored out of the sight and reach of children.
Protection	Keep the container tightly closed in a dry, cool, and well-ventilated place.
Environment	Protect from light and moisture.

Disposal Instructions

Unused or expired product must be discarded according to official waste handling regulations.

Regulatory Compliance: Dispose of contents and container in accordance with local, national, and international regulations.
Environmental Rule: The product must not be discharged to sewer systems or surface water, as required for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.